Jam

Barton Gold completed Phase 1 drilling at its Tunkillia Gold Project ahead of schedule and under budget, drilling 18,893m across 209 holes in 62 days. The drilling targets the high-grade S1 area, modeled to contain 206koz Au, with initial assays expected soon. Phase 2 drilling is planned for 2026. The aim is to upgrade resources to JORC Indicated/Measured categories for future development and secure project financing.

Thermo Fisher Scientific (NYSE: TMO) announced the pricing of a €2.1 billion euro-denominated notes offering via its finance subsidiary. The offering includes €1 billion in floating rate notes due 2027 and €1.1 billion in 3.628% fixed rate notes due 2035, both priced at 100%. Closing is expected around December 1, 2025, subject to conditions. Proceeds are intended for general corporate purposes, including potential acquisitions, debt management, and capital investments.

Ascentage Pharma’s olverembatinib demonstrated promising Phase Ib results in SDH-deficient GIST, with an ORR of 23.1% and CBR of 84.6%. Median PFS reached 25.7 months. Translational analyses revealed CD36 overexpression and dysregulated lipid metabolism. Olverembatinib reduced CD36 and lipid uptake while inhibiting HIF, FGFR, and VEGFR pathways. It holds Breakthrough Therapy Designation in China. A global Phase III trial (POLARIS-3, NCT06640361) is ongoing.

GE HealthCare (GEHC) declared a Q4 2025 cash dividend of $0.035 per share, payable February 13, 2026, to shareholders of record on January 9, 2026. This decision reflects the company’s commitment to shareholder value amidst increasing demand within the healthcare industry and technological advancements. GE HealthCare, a $19.7 billion global leader, focuses on medical technology, pharmaceutical diagnostics, and AI-enabled solutions. The company aims to optimize hospital efficiency and improve patient outcomes.

Fuzzy’s Taco Shop introduces the limited-edition Jingle Berry ‘Rita from November 24th to December 31st. This holiday cocktail blends their signature Frozen House Margarita with blackberry syrup, Ole Smoky Blackberry Moonshine, and a Black Cherry White Claw topper. The seasonal offering aims to drive traffic and increase revenue during the holidays. Fuzzy’s Taco Shop, franchised by Dine Brands Global, operates 109 restaurants across 15 states. The Jingle Berry ‘Rita is available at participating locations while supplies last.

Aussie (Procter & Gamble) launched its Ultra Wonder curl care line on November 24, 2025. The three-product collection (Daily Mist, Treatment, Gel Crème), priced at $9.99 each, simplifies routines with multi-functional formulas containing amino acids and strengthening lipids. Targeting consumers seeking efficient beauty solutions, Ultra Wonder promises treatment-level care, curl definition, and frizz control. The line is available on Amazon, TikTok Shop, and in major retail stores. Aussie emphasizes accessible pricing and time-saving benefits, aiming to compete with established brands in the curl care market.

Union Pacific (UNP) and the International Brotherhood of Boilermakers (IBB) reached a labor agreement ensuring job security for boilermakers amidst the proposed merger with Norfolk Southern, which aims to create the first coast-to-coast rail network in the U.S. This is the fourth such agreement UNP has secured with national unions, signaling growing confidence in the merger’s potential benefits. The deal seeks to mitigate potential labor disruptions and establish a more efficient and resilient supply chain, benefiting employees, customers, and the American economy. Analysts predict this move will optimize freight transportation.

Wingspire Equipment Finance has provided over $130 million in equipment financing to six portfolio companies of a major private equity sponsor, including a $40+ million transaction. This partnership highlights the growing trend of private equity firms seeking specialized equipment financing to optimize capital structures. Spanning energy, healthcare, and aerospace, the financing enables these companies to boost capacity and modernize infrastructure. Wingspire’s speed, scale, and alignment with private equity risk profiles are key differentiators, facilitating efficient funding and allowing firms to focus on core competencies.

NervGen Pharma announced positive Q3 2025 results highlighting progress in the CONNECT SCI study, where NVG-291 showed clinically meaningful improvements in spinal cord injury patients versus placebo. 75% of the NVG-291 group reported global improvement compared to 33% in the placebo arm. The FDA confirmed potential regulatory pathways for NVG-291, with an End-of-Phase 2 meeting planned for early 2026. A $10.05M private placement was completed. Cash reserves stood at $11.4M. Preclinical data showed promise in hearing loss and nerve injury models.

Qudian Inc. reported its Q3 2025 unaudited financial results, revealing a sharp 84.5% drop in revenue to RMB8.5 million due to the last-mile delivery business phase-out. However, net income attributable to shareholders surged to RMB409.9 million, driven by increased investment income and gains on derivative instruments. The company maintains a strong cash position and continues its share repurchase program. Qudian’s future hinges on successful diversification and strategic capital allocation.